124 related articles for article (PubMed ID: 12676906)
1. Rapid, inexpensive scanning for all possible BRCA1 and BRCA2 gene sequence variants in a single assay: implications for genetic testing.
Bounpheng M; McGrath S; Macias D; van Orsouw N; Suh Y; Rines D; Vijg J
J Med Genet; 2003 Apr; 40(4):e33. PubMed ID: 12676906
[No Abstract] [Full Text] [Related]
2. US court reverses gene patent ruling for BRCA1 and BRCA2.
Brower V
Lancet Oncol; 2011 Sep; 12(9):835. PubMed ID: 21984989
[No Abstract] [Full Text] [Related]
3. Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.
Evans DG; Bulman M; Young K; Gokhale D; Lalloo F
J Med Genet; 2003 Sep; 40(9):e107. PubMed ID: 12960223
[No Abstract] [Full Text] [Related]
4. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
5. DHPLC/SURVEYOR nuclease: a sensitive, rapid and affordable method to analyze BRCA1 and BRCA2 mutations in breast cancer families.
Pilato B; De Summa S; Danza K; Papadimitriou S; Zaccagna P; Paradiso A; Tommasi S
Mol Biotechnol; 2012 Sep; 52(1):8-15. PubMed ID: 22072316
[TBL] [Abstract][Full Text] [Related]
6. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
7. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
[No Abstract] [Full Text] [Related]
8. EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients.
Caux-Moncoutier V; Castéra L; Tirapo C; Michaux D; Rémon MA; Laugé A; Rouleau E; De Pauw A; Buecher B; Gauthier-Villars M; Viovy JL; Stoppa-Lyonnet D; Houdayer C
Hum Mutat; 2011 Mar; 32(3):325-34. PubMed ID: 21120943
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
10. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
11. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
[TBL] [Abstract][Full Text] [Related]
13. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
16. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
17. Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
Lynce F; Isaacs C
J Natl Compr Canc Netw; 2016 Jun; 14(6):809-12. PubMed ID: 27283172
[No Abstract] [Full Text] [Related]
18. Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis.
Velasco E; Infante M; Durán M; Esteban-Cardeñosa E; Lastra E; García-Girón C; Miner C
Electrophoresis; 2005 Jun; 26(13):2539-52. PubMed ID: 15937982
[TBL] [Abstract][Full Text] [Related]
19. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
[TBL] [Abstract][Full Text] [Related]
20. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
